Payment overview · 2025
General Payments
$431.86
11 reported records · 8 companies
Healthcare provider profile · identity verified
Scott Russell, DO
Allopathic & Osteopathic Physicians|Family Medicine · BERMUDA DUNES, CA · NPI 1073581237
Verified facts
What the public records show
CMS Open Payments records show Scott Russell, DO received $431.86 in general payments during 2025 across 11 reported records.
ViiV Healthcare Company accounted for 68.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 156 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $295.61 | 68.5% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $25.76 | 6.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $23.41 | 5.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $20.21 | 4.7% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $17.67 | 4.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.40 | 4.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.13 | 3.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.67 | 3.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $431.86 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $171.69 | 3 | 2025 |
Source payment records
|
|||||
| RUKOBIA Normalized: rukobia |
Drug | ViiV Healthcare Company | $123.92 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $25.76 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $23.41 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $23.41 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $20.21 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $16.13 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.13 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.67 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 156 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 54 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
36 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
36 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
156 | 50 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 713 | 215 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 688 | 232 |
| Amlodipine Besylate | Amlodipine Besylate | 601 | 197 |
| Levothyroxine Sodium | Levothyroxine Sodium | 481 | 151 |
| Losartan Potassium | Losartan Potassium | 468 | 152 |
| Tamsulosin Hcl | Tamsulosin Hcl | 425 | 142 |
| Omeprazole | Omeprazole | 332 | 129 |
| Lisinopril | Lisinopril | 322 | 100 |
| Gabapentin | Gabapentin | 297 | 110 |
| Metoprolol Succinate | Metoprolol Succinate | 277 | 88 |
| Finasteride | Finasteride | 257 | 87 |
| Sertraline Hcl | Sertraline Hcl | 230 | 84 |
| Fluticasone Propionate | Fluticasone Propionate | 217 | 97 |
| Metformin Hcl | Metformin Hcl | 209 | 72 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 198 | 80 |
| Furosemide | Furosemide | 181 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 176 | 61 |
| Trazodone Hcl | Trazodone Hcl | 174 | 56 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 170 | 57 |
| Tramadol Hcl | Tramadol Hcl | 168 | 65 |
| Clopidogrel | Clopidogrel Bisulfate | 166 | 54 |
| Eliquis | Apixaban | 156 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 145 | 51 |
| Alprazolam | Alprazolam | 137 | 47 |
| Oxybutynin Chloride | Oxybutynin Chloride | 135 | 47 |
| Ozempic | Semaglutide | 132 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 128 | 44 |
| Bupropion Xl | Bupropion Hcl | 120 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 120 | 34 |
| Ibuprofen | Ibuprofen | 118 | 46 |
| Carvedilol | Carvedilol | 115 | 40 |
| Zolpidem Tartrate | Zolpidem Tartrate | 111 | 17 |
| Memantine Hcl | Memantine Hcl | 110 | 28 |
| Tizanidine Hcl | Tizanidine Hcl | 109 | 56 |
| Meloxicam | Meloxicam | 105 | 34 |
| Metformin Hcl Er | Metformin Hcl | 100 | 28 |
| Montelukast Sodium | Montelukast Sodium | 97 | 31 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 96 | 37 |
| Escitalopram Oxalate | Escitalopram Oxalate | 94 | 32 |
| Temazepam | Temazepam | 93 | 25 |
| Potassium Chloride | Potassium Chloride | 87 | 28 |
| Atenolol | Atenolol | 84 | 29 |
| Donepezil Hcl | Donepezil Hcl | 84 | 22 |
| Famotidine | Famotidine | 80 | 31 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 76 | 24 |
| Nitroglycerin | Nitroglycerin | 75 | 46 |
| Simvastatin | Simvastatin | 70 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 69 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 68 | 25 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 66 | 46 |
| Duloxetine Hcl | Duloxetine Hcl | 66 | 16 |
| Xarelto | Rivaroxaban | 66 | 19 |
| Glimepiride | Glimepiride | 64 | 21 |
| Methylprednisolone | Methylprednisolone | 64 | 53 |
| Azithromycin | Azithromycin | 63 | 55 |
| Lorazepam | Lorazepam | 63 | 20 |
| Lovastatin | Lovastatin | 62 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 62 | 16 |
| Amoxicillin | Amoxicillin | 60 | 47 |
| Pregabalin | Pregabalin | 60 | 23 |
| Acyclovir | Acyclovir | 58 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 58 | 19 |
| Allopurinol | Allopurinol | 56 | 22 |
| Mounjaro | Tirzepatide | 54 | suppressed |
| Synthroid | Levothyroxine Sodium | 54 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 52 | 40 |
| Quetiapine Fumarate | Quetiapine Fumarate | 50 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 46 | 17 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 44 | 21 |
| Buspirone Hcl | Buspirone Hcl | 43 | 11 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 43 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 43 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 42 | 17 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 42 | 32 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 42 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | 29 |
| Ezetimibe | Ezetimibe | 41 | 11 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 41 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 40 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 39 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | 15 |
| Myrbetriq | Mirabegron | 38 | 15 |
| Valacyclovir | Valacyclovir Hcl | 38 | 20 |
| Clonidine Hcl | Clonidine Hcl | 37 | 19 |
| Jardiance | Empagliflozin | 36 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 34 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 33 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 33 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 33 | 26 |
| Repatha Sureclick | Evolocumab | 32 | 11 |
| Valsartan | Valsartan | 32 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 31 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | 12 |
| Mirtazapine | Mirtazapine | 31 | 15 |
| Sildenafil Citrate | Sildenafil Citrate | 31 | suppressed |
| Baclofen | Baclofen | 30 | 15 |
| Cephalexin | Cephalexin | 30 | 19 |
| Estradiol | Estradiol | 30 | 13 |
| Latanoprost | Latanoprost | 30 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 30 | 18 |
| Meclizine Hcl | Meclizine Hcl | 28 | 13 |
| Clotrimazole | Clotrimazole | 27 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Spironolactone | Spironolactone | 26 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Naproxen | Naproxen | 24 | suppressed |
| Ramipril | Ramipril | 24 | suppressed |
| Cholestyramine Light | Cholestyramine | 23 | suppressed |
| Clonazepam | Clonazepam | 23 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 23 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 22 | 19 |
| Diltiazem 24hr Er | Diltiazem Hcl | 21 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 20 | 12 |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 20 | suppressed |
| Prednisone | Prednisone | 20 | 16 |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 18 |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Anastrozole | Anastrozole | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Diazepam | Diazepam | 13 | 11 |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 11 | suppressed |
| Hydroxyurea | Hydroxyurea | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $431.86 · 11 records | ViiV Healthcare Company | APRETUDE, BREZTRI, ELIQUIS, MOUNJARO, NURTEC ODT, OTEZLA, REPATHA, RUKOBIA, TRELEGY ELLIPTA, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error